Investment PromotionGovernment & regulators

BoI Med-Tech Promotion 2024-2027

BoI Med-Tech Promotion 2024-2027 is the Board of Investment of Thailand-administered targeted investment-promotion programme for medical-technology investments. Provides tier-A tax holidays, customs-duty exemptions, and Smart Visa privileges for medical-devices manufacturing, biopharma R&D, smart-hospital technology, and digital-health platform investments. Aligns with Thailand's structural medical-tourism export base and the EEC bio-economy industrial-cluster strategy.

Profile overview

BoI Med-Tech Promotion 2024-2027 is the Board of Investment of Thailand-administered targeted investment-promotion programme for medical-technology investments. Provides tier-A tax holidays, customs-duty exemptions, and Smart Visa privileges for medical-devices manufacturing, biopharma R&D, smart-hospital technology, and digital-health platform investments. Aligns with Thailand's structural medical-tourism export base and the EEC bio-economy industrial-cluster strategy.

Public-record references
Data as of: 2024-2026

Business segments / Programs

Medical Devices Manufacturing

Tier-A tax holidays for device makers

BoI's Activity 4.2.1 covers medical-device manufacturing with 8-year CIT exemption, no machinery import duty, and raw-material duty exemptions. Over 60 medical-device FDI projects approved under 2022-2024 cycles.

Biopharma R&D

Smart Visa privileges for biopharma

Biopharma R&D facilities in EEC Bio-Economy zones qualify for 10-year CIT exemption and Smart Visa for eligible foreign researchers. Thailand hosted $121.7M in biopharma FDI approvals in 2023.

Digital Health

Smart-hospital and health-tech platforms

Digital-health platforms with AI diagnostics, telemedicine, or hospital information systems qualify for 5-year CIT exemption under BoI Activity 7.29. Over 25 digital-health projects approved in 2023-2024.

Sector position β€” BoI med-tech promotion vs comparable programmes

BoI Med-Tech 2024-2027

Key activity

Medical devices, biopharma, digital health

CIT exemption

5-10 years

FDI approvals 2023

$188.4M+

BoI Semiconductor (EEC)

Key activity

IC packaging, PCB manufacturing

CIT exemption

8-10 years

FDI approvals 2023

$637.7M+

BoI BCG (Bio-Circular-Green)

Key activity

Biorefinery, bioplastics, biofuels

CIT exemption

8 years

FDI approvals 2023

$139.1M+

Malaysia BioNexus

Key activity

Biopharma, biotechnology, agritech

CIT exemption

5-15 years

FDI approvals 2023

MYR 3.2B

Watchpoints 2025-2026

Policy

EEC bio-economy cluster buildout

EEC Bio-Economy Industrial Estate in Chachoengsao is targeting 30 anchor tenants by 2026. BoI med-tech privileges are integrated with EEC zone incentives, creating stacked benefits for qualifying investors.

Competition

Singapore and Malaysia competing for biopharma FDI

Singapore's EDB and Malaysia's MIDA are both aggressively targeting Southeast Asian biopharma FDI. Thailand needs to accelerate regulatory streamlining to remain competitive on time-to-operate.

Opportunity

Medical tourism export synergies

Thailand's 3.5M medical-tourism visitors annually create a natural demand-side anchor for locally manufactured devices. BoI is developing a local-sourcing incentive for hospitals using Thai-made devices.

Related Market profiles

Peers, parents, partners, agencies, and other Investment Promotion actors.

Reports featuring this profile

Related Market profiles

BoI Med-Tech Promotion 2024-2027 - Market Atlas Β· Insight